Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hodgkin’s Lymphoma Treatment Market Growth From $3.83 Billion In 2026 To $5.08 Billion By 2030 At A CAGR Of 7.3%
The hodgkin’s lymphoma treatment market has experienced robust growth in recent years. It is projected to expand from $3.56 billion in 2025 to $3.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. This historical expansion can be attributed to several factors including the rising incidence of hodgkin’s lymphoma, enhanced awareness leading to early diagnosis, increased adoption of chemotherapy and radiation therapy, the development of oncology healthcare infrastructure, and augmented government funding for cancer research.
The hodgkin’s lymphoma treatment market size is anticipated to expand significantly in the near future. It is projected to reach $5.08 billion by 2030, showing a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period is largely driven by the increasing adoption of immunotherapy and targeted therapies, the wider availability of stem cell transplantation, a rising demand among patients for personalized treatments, the expansion of cancer centers into emerging markets, and enhanced insurance coverage along with reimbursement support. Key trends expected over this period include advancements in diagnostic imaging technology, innovations within immunotherapy and targeted therapies, the development of minimally invasive treatment choices, ongoing research and development in stem cell transplantation, and the integration of digital health and telemedicine for follow-up care.
Get A Free Sample Report With In-Depth Market Insights:
Hodgkin’s Lymphoma Treatment Market Growth Momentum: What Factors Are Shaping Demand?
The rising occurrence of Hodgkin’s lymphoma is anticipated to drive expansion in the Hodgkin’s lymphoma treatment market moving ahead. This condition, Hodgkin’s lymphoma, is a lymphatic system cancer marked by atypical Reed–Sternberg cells within lymph nodes, primarily impacting B-lymphocytes, frequently manifesting as enlarged, painless glands, elevated body temperature, nocturnal perspiration, and diminished body mass. The prevalence of Hodgkin’s lymphoma is increasing, attributed to greater exposure to risk factors including tobacco use, excess weight, high blood pressure, and evolving socioeconomic circumstances across numerous areas, which collectively contribute to an elevated incidence of the disease over time. Treatment for Hodgkin’s lymphoma assists in managing the disease by specifically targeting and eradicating malignant lymphocytes using therapeutic approaches like chemotherapy, radiation therapy, or immunotherapy. Such treatment enhances patient results through mitigating disease advancement, attaining periods of remission, and boosting overall survival percentages. For example, by October 2025, the American Cancer Society, a US-based nonprofit organization, projects that Hodgkin lymphoma in the United States will comprise approximately 8,720 new cases, with 4,840 affecting males and 3,880 affecting females, alongside an estimated 1,150 deaths, split between 720 males and 430 females. Consequently, the growing frequency of Hodgkin’s lymphoma is stimulating expansion within the Hodgkin’s lymphoma treatment market.
Hodgkin’s Lymphoma Treatment Market Segmentation: How Does The Market Break Down By Category?
The hodgkin’s lymphoma treatment market covered in this report is segmented –
1) By Type of Treatment: Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy
2) By Disease Type: Classical Hodgkin Lymphoma (CHL), Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
3) By Treatment Stage: Early-Stage, Advanced-Stage, Relapsed
4) By Stem Cell Transplantation: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
5) By End-Use: Hospitals, Specialty Clinics, Cancer Centers, Ambulatory Care Centers, Home Healthcare Services
Subsegments:
1) By Chemotherapy: Combination Chemotherapy, Single Agent Chemotherapy, High Dose Chemotherapy with Stem Cell Transplantation
2) By Radiation Therapy: External Beam Radiation Therapy, Proton Beam Radiation Therapy, Intensity Modulated Radiation Therapy
3) By Targeted Therapy: Monoclonal Antibody Therapy, Antibody Drug Conjugate Therapy, Small Molecule Inhibitor Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitor Therapy, Chimeric Antigen Receptor T Cell Therapy, Cytokine Based Immunotherapy
Hodgkin’s Lymphoma Treatment Market Trends Redefining Industry Growth
Companies operating within the Hodgkin’s lymphoma treatment market are concentrating on developing advanced therapies, including front-line targeted combination treatments, to enhance their effectiveness, mitigate treatment-related illness, and expand initial options for patients suffering from advanced forms of the disease. Front-line targeted combination therapies involve utilizing two or more precision medicines together as the initial intervention, aiming to concurrently affect multiple disease-driving pathways, thereby improving response rates and delaying the onset of resistance in newly diagnosed patients. For example, in June 2025, Takeda, a Japan-based pharmaceutical company, secured European Commission approval for ADCETRIS when combined with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) for adults with newly diagnosed Stage IIb with risk factors, Stage III, or Stage IV Hodgkin lymphoma. This approval was based on findings from the Phase 3 HD21 trial, which revealed superior safety and non-inferior progression-free survival compared to standard eBEACOPP chemotherapy. This particular front-line targeted combination therapy integrates a targeted ADC foundation, a chemotherapy regimen optimized to reduce acute toxicity, and broadened indications for frontline use, marking a substantial progression in Hodgkin’s lymphoma care.
Hodgkin’s Lymphoma Treatment Market Key Players Shaping Industry Direction
Major companies operating in the hodgkin’s lymphoma treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Seagen Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., BeiGene Ltd., Innovent Biologics Inc., HUTCHMED (China) Limited, Aurigene Discovery Technologies Limited, ADC Therapeutics SA, CStone Pharmaceuticals, Emcure Pharmaceuticals Ltd., Sorrento Therapeutics Inc.
View The Full Hodgkin’s Lymphoma Treatment Market Report:
Hodgkin’s Lymphoma Treatment Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the hodgkin’s lymphoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hodgkin’s lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
